<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>12(3)</volume><submitter>Comunale BA</submitter><pubmed_abstract>&lt;b>Introduction:&lt;/b> Prior research explores whether seasonal and childhood vaccines mitigate the risk of SARS-CoV-2 infection. Although there are trials investigating COVID-19 infection in response to the effects of the oral poliovirus vaccine (OPV), there has been no prior research assessing COVID-19 outcomes in recently immunized adults with the inactivated poliovirus vaccine (IPV). &lt;b>Methods:&lt;/b> SARS-CoV-2 infection and COVID-19 symptoms were analyzed across a cohort of 282 adults who received an IPV booster. Bivariate and multivariate regression models explored associations among variables related to vaccination histories and COVID-19 outcomes. &lt;b>Results:&lt;/b> One year post-IPV inoculation, participants who had never received OPV were more likely to test positive for SARS-CoV-2 and </pubmed_abstract><journal>Vaccines</journal><pagination>219</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10974902</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Inactivated Poliovirus Vaccine Booster Reduces the Likelihood of COVID-19 Outcomes in Individuals Primed with Oral Poliovirus Vaccination.</pubmed_title><pmcid>PMC10974902</pmcid><pubmed_authors>Hsu YJ</pubmed_authors><pubmed_authors>Larson RJ</pubmed_authors><pubmed_authors>Engineer LD</pubmed_authors><pubmed_authors>Azodoh C</pubmed_authors><pubmed_authors>Singh A</pubmed_authors><pubmed_authors>Jackson-Ward E</pubmed_authors><pubmed_authors>Comunale BA</pubmed_authors></additional><is_claimable>false</is_claimable><name>Inactivated Poliovirus Vaccine Booster Reduces the Likelihood of COVID-19 Outcomes in Individuals Primed with Oral Poliovirus Vaccination.</name><description>&lt;b>Introduction:&lt;/b> Prior research explores whether seasonal and childhood vaccines mitigate the risk of SARS-CoV-2 infection. Although there are trials investigating COVID-19 infection in response to the effects of the oral poliovirus vaccine (OPV), there has been no prior research assessing COVID-19 outcomes in recently immunized adults with the inactivated poliovirus vaccine (IPV). &lt;b>Methods:&lt;/b> SARS-CoV-2 infection and COVID-19 symptoms were analyzed across a cohort of 282 adults who received an IPV booster. Bivariate and multivariate regression models explored associations among variables related to vaccination histories and COVID-19 outcomes. &lt;b>Results:&lt;/b> One year post-IPV inoculation, participants who had never received OPV were more likely to test positive for SARS-CoV-2 and </description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Feb</publication><modification>2026-04-08T15:24:05.429Z</modification><creation>2025-04-05T23:18:29.405Z</creation></dates><accession>S-EPMC10974902</accession><cross_references><pubmed>38543853</pubmed><doi>10.3390/vaccines12030219</doi></cross_references></HashMap>